Abstract:
BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospitalized children with diarrhea aged under 5 years and their family caregivers at three hospitals in Phetchabun province, Thailand during May 2013 and February 2014. The severity of diarrhea was assessed using the Vesikari severity scoring system while the HRQoL was assessed using the EQ-5D-3L. RESULTS:The mean EQ-5D utility of children with all-causes diarrhea was 0.604. The utility of the rotavirus diarrhea group was significantly lower than that of the non-rotavirus diarrhea group (0.593 vs. 0.612; p-value = 0.040). The family caregiver's utility was 0.964 at baseline and significantly decreased to 0.620 (p-value = 0.041) when their children were hospitalized with diarrhea. In multiple regression analyses, severity but not rotavirus infection had significant negative impacts on the utility of both the children and their caregivers. CONCLUSION:Diarrhea, either caused by rotavirus or non-rotavirus infection, resulted in substantial negative impacts on the quality of life of both the children and their caregivers.
journal_name
Expert Rev Pharmacoecon Outcomes Resjournal_title
Expert review of pharmacoeconomics & outcomes researchauthors
Rochanathimoke O,Riewpaiboon A,Postma MJ,Thinyounyong W,Thavorncharoensap Mdoi
10.1080/14737167.2018.1386561subject
Has Abstractpub_date
2018-04-01 00:00:00pages
215-222issue
2eissn
1473-7167issn
1744-8379journal_volume
18pub_type
杂志文章,多中心研究abstract:OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2020.1800457
更新日期:2020-08-01 00:00:00
abstract:OBJECTIVES:We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations. STUDY DE...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2015.978292
更新日期:2015-04-01 00:00:00
abstract::The European Organisation for Research and Treatment of Cancer (EORTC) 50th Anniversary Conference was held on the 15-16 March in Brussels, Belgium. More than 1100 participants (including EORTC members and staff, national research organizations, health authorities, patient advocacy groups, European Commission, cancer ...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type:
doi:10.1586/erp.12.32
更新日期:2012-08-01 00:00:00
abstract::Chronic obstructive pulmonary disease is a major cause of morbidity and mortality throughout the world. Standard management includes avoidance of causative factors such as smoking, and pharmacological therapy with combinations of inhaled and/or oral bronchodilators and corticosteroids. Lung transplantation is an estab...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.3.6.729
更新日期:2003-12-01 00:00:00
abstract::A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.7.6.577
更新日期:2007-12-01 00:00:00
abstract::Ankylosing spondylitis (AS) is a complex systemic rheumatological disease which often causes severe disability and impaired quality of life (QoL). We searched the PubMed/MEDLINE electronic database for available literature on QoL and its predictors in patients with AS. Recent evidence indicates that AS patients have p...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2014.957679
更新日期:2014-12-01 00:00:00
abstract::This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2014.927315
更新日期:2014-10-01 00:00:00
abstract::We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2013.838027
更新日期:2013-10-01 00:00:00
abstract::The Resonance metallic stent is a new wire-based ureteral stent that was initially developed for patients with malignant ureteral obstruction. Potential advantages over traditional stents include resistance to encrustation and to external compression, allowing for increased dwell times and the maintenance of upper tra...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/erp.09.74
更新日期:2010-02-01 00:00:00
abstract::Electronic medical records (EMRs) have become a common source of data for outcomes research. This review discusses trends in EMR data use for outcomes research as well as strengths and limitations, and likely future developments to help optimize value and use of EMR data for outcomes research. EMR-based studies report...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.13.7
更新日期:2013-04-01 00:00:00
abstract:BACKGROUND:This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first ...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2019.1632194
更新日期:2020-06-01 00:00:00
abstract::The rapid rise in health care expenses has resulted in an increased interest in the cost of treatments from a cost-effectiveness point of view for management purposes and in a reimbursement setting. The economics of radiotherapy within the global context of health care, and more specifically of cancer therapy, are dis...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.3.4.497
更新日期:2003-08-01 00:00:00
abstract::In this article, we will focus on how preferences and utilities are measured, including the strengths and limitations of various approaches, discuss their use in estimating quality-adjusted life-years (QALYs) and make some recommendations for further research. Preferences are either measured using direct (visual analo...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.11.100
更新日期:2012-02-01 00:00:00
abstract::Given the lack of evidence from randomized controlled trials and large prospective studies, controversy exists regarding the optimal treatment strategy for early stage prostate cancer. The impact of various treatments on health-related quality of life has become an increasingly important but controversial issue. The l...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.4.3.277
更新日期:2004-06-01 00:00:00
abstract::The incidence of melanoma has been climbing steadily since the early 1970s. Although melanoma can be successfully cured by surgical excision in its early stages, it is the most common fatal form of skin cancer. The most critical factors in determining the prognosis for patients with melanoma are primary tumor thicknes...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.4.6.667
更新日期:2004-12-01 00:00:00
abstract::This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Lo...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.7.1.49
更新日期:2007-02-01 00:00:00
abstract::Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to re...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.7.5.445
更新日期:2007-10-01 00:00:00
abstract::Evaluation of: Levin LA, Wallentin L, Bernfort L et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes results from the PLATO trial. Value Health 16(4), 574-580 (2013). Antiplatelet therapy is considered essential treatment for acute coronary syndromes with or...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 评论,杂志文章
doi:10.1586/14737167.2014.861743
更新日期:2014-02-01 00:00:00
abstract::This article reviews the literature reporting empirically determined symptom clusters in patients with metastatic cancer. A literature search was conducted on symptom clusters within heterogeneous metastatic cancer patient populations using MEDLINE, EMBASE, and CINAHL. Studies examining predetermined symptom clusters ...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.12.41
更新日期:2012-10-01 00:00:00
abstract::Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality worldwide. The chronic progressive disease is accompanied by a high loss of health-related quality of life (HRQoL). The available drugs usually only have symptomatic effects; therefore, non-pharmacological therapies are ...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2020.1734455
更新日期:2020-02-01 00:00:00
abstract:INTRODUCTION:This article is part of the series "How to Prepare a Systematic Review (SR) of Economic Evaluations (EE) for Informing Evidence-based Healthcare Decisions" in which a five-step-approach for conducting a SR of EE is proposed. Areas covered: This paper explains the data extraction process, the risk of bias a...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1080/14737167.2016.1246961
更新日期:2016-12-01 00:00:00
abstract::Up to 10% of the adult population in most countries may be affected by chronic bronchitis or chronic obstructive pulmonary disease. The course of the disease is characterized by frequent exacerbations with increased respiratory symptoms. Exacerbations are the most important cause of morbidity and mortality, and signif...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.5.4.423
更新日期:2005-08-01 00:00:00
abstract::This review examines the national trends in out-of-pocket and high economic burden of prescription drug expenditures by elderly people aged 65 years and older. From 1992 to 2000, prescription out-of-pocket drug expenditures increased at an annual rate of 7%. During this period the proportion of elderly without prescri...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.5.3.297
更新日期:2005-06-01 00:00:00
abstract:INTRODUCTION:Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several subtypes of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a m...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2019.1536549
更新日期:2019-04-01 00:00:00
abstract::Descemet's stripping endothelial keratoplasty (DSEK) is a relatively new technique that is rapidly replacing full-thickness procedures for those patients needing corneal transplantation for endothelial dysfunction. Benefits of DSEK include a faster recovery, reduced astigmatism, fewer postoperative complications and r...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.7.2.137
更新日期:2007-04-01 00:00:00
abstract::Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that i...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.11.14
更新日期:2011-04-01 00:00:00
abstract:OBJECTIVES:This cross-sectional study examined the prevalence and burden of major depressive disorder (MDD) among adults in urban China. METHODS:Data were included from the 2012 China National Health and Wellness Survey. Respondents self-reporting physician diagnosis of depression and screening positive for MDD (Patie...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2016.1102062
更新日期:2016-06-01 00:00:00
abstract::Quality-adjusted life-years (QALYs) play an important role in reimbursement decisions when one of the criteria is the cost-effectiveness of the health technology. While for many generic QALYs (e.g., based on the EQ-5D) are viewed as the gold standard, there has been a considerable increase in interest in using conditi...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.8.5.453
更新日期:2008-10-01 00:00:00
abstract::Recently, the person tradeoff method has received much attention because it directs one to value health improvements of those other than one's self. As a result, several researchers have suggested that the person tradeoff measures preferences in pharmaceutical and health economic analysis more accurately than the stan...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.5.6.677
更新日期:2005-12-01 00:00:00
abstract::The primary objective of this review is to develop a conceptual model for Crohn's disease (CD) outlining the disease burden for patients, healthcare systems and wider society, as reported in the scientific literature. A search was conducted using MEDLINE, PsycINFO, EconLit, Health Economic Evaluation Database and Cent...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2015.1045883
更新日期:2015-01-01 00:00:00